Schering-Plough Relief on Partner Earnings
by Jon C. Ogg
24/7 Wall St.
Schering-Plough Corp. (SGP) is probably breathing a sigh of relief this morning after Merck's earnings as it is partners with the drug giant on Vytorin and Zetia for cholesterol treatments.
The combined Vytorin & Zetia franchise was noted as having some $5.2 Billion in 2007 annual sales, with some $1.5 Billion being reported in the fourth quarter alone.
Merck (MRK) did disclose some 50 lawsuits over these sales and noted that it is complying and cooperating with investigations. But the good news is that the company's guidance wasn't sharply changed.
Continue reading article at 24/7 Wall Street...
24/7 Wall St. is a regular contributor to BioHealth Investor
________________
24/7 Wall St.
Schering-Plough Corp. (SGP) is probably breathing a sigh of relief this morning after Merck's earnings as it is partners with the drug giant on Vytorin and Zetia for cholesterol treatments.
The combined Vytorin & Zetia franchise was noted as having some $5.2 Billion in 2007 annual sales, with some $1.5 Billion being reported in the fourth quarter alone.
Merck (MRK) did disclose some 50 lawsuits over these sales and noted that it is complying and cooperating with investigations. But the good news is that the company's guidance wasn't sharply changed.
Continue reading article at 24/7 Wall Street...
24/7 Wall St. is a regular contributor to BioHealth Investor
________________
posted by Nico at
4:42 PM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home